Know Cancer

forgot password

Biomarkers in Thyroid Cancer

18 Years
90 Years
Open (Enrolling by invite only)
Cancer of the Thyroid, Neoplasms, Thyroid, Thyroid Adenoma, Thyroid Cancer, Thyroid Carcinoma

Thank you

Trial Information

Biomarkers in Thyroid Cancer

This protocol requires the collection of blood (5 ml), fine-needle aspirate biopsies (FNAB),
and post-surgical thyroid cancer tissue. The post surgical tissue includes fresh-frozen
tissue that is considered waste and in excess of that required for pathologic diagnosis, and
archived formalin-fixed, paraffin-embedded tissue (FFPE). The blood will be used as a
substrate for assessing known markers, including microRNA expression patterns that may be
useful to predict disease and thyroid cancer morphotype. The FNABs will be used to screen
the potential of markers for pre-operative diagnosis. The post-surgical fresh-frozen thyroid
cancer tissue will be used to isolate DNA and RNA in order to assess somatic mutations (RAS
and PAX8/PPAR-gamma rearrangement) and messenger RNA, and microRNA expression patterns. The
FFPE tissue will be used to obtain H&E and unstained slides to validate results using
immunohistochemistry. The goal of these studies is to define molecular markers that will
accurately distinguish benign from malignant disease and the multiple thyroid cancer
phenotypes. Current methods of distinguishing benign from malignant disease requires a
detailed post-surgical analysis and no known markers have yet been identified to reliably
differentiate the multiple thyroid cancer morphotypes.

Inclusion Criteria:

- Patient with palpable thyroid nodule suspicious for thyroid neoplasm

- Patient selected to undergo fine needle biopsy for cytologic diagnosis

- Male (18 years of age or older)

- Female (18 years of age or older)

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Distinguish follicular adenoma from follicular carcinoma

Outcome Description:

Biomarkers will be identified to distinguish benign follicular adenoma from follicular carcinoma of the thyroid.

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Norman Eberhardt, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic


United States: Institutional Review Board

Study ID:




Start Date:

June 2011

Completion Date:

April 2014

Related Keywords:

  • Cancer of the Thyroid
  • Neoplasms, Thyroid
  • Thyroid Adenoma
  • Thyroid Cancer
  • Thyroid Carcinoma
  • thyroid cancer
  • thyroid neoplasm
  • thyroid adenoma
  • Adenoma
  • Neoplasms
  • Carcinoma
  • Thyroid Neoplasms
  • Thyroid Diseases



Mayo Clinic in RochesterRochester, Minnesota  55905